A New Topical Treatment for Resistant Herpes Simplex Infections
| Autor: | G. Tricot, Graciela Andrei, Nathan Clumeck, E. De Clercq, Catherine Sadzot-Delvaux, Marie-Christine Gerard, Robert Snoeck |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Foscarnet
Simplexvirus food.ingredient viruses AIDS-Related Opportunistic Infections Mucocutaneous zone Drug Resistance Organophosphonates Drug resistance medicine.disease_cause Antiviral Agents Cytosine Immunocompromised Host chemistry.chemical_compound Organophosphorus Compounds food medicine Humans business.industry virus diseases Herpes Simplex General Medicine Virology Herpes simplex virus chemistry business Thymidine Cidofovir medicine.drug |
| Zdroj: | New England Journal of Medicine. 329:968-969 |
| ISSN: | 1533-4406 0028-4793 |
| DOI: | 10.1056/nejm199309233291317 |
| Popis: | To the Editor: For persistent mucocutaneous infections due to herpes simplex virus (HSV) in immunosuppressed patients, acyclovir is the drug of choice1. Foscarnet is an alternative agent,2,3 but it too may lead to resistance. A new approach to the therapy of HSV infections is based on the use of an acyclic nucleoside phosphonate, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), a potent and selective inhibitor of various DNA viruses, including HSV types 1 and 2 and thymidine kinase-deficient mutants of HSV4,5. We used HPMPC (1 percent, in Beeler base or Orabase), applied topically once a day on three consecutive days a . . . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|